Zobrazeno 1 - 10
of 1 149
pro vyhledávání: '"Robert J Motzer"'
Autor:
Thomas Powles, Laurence Albiges, David F McDermott, Michael B Atkins, Toni K Choueiri, Bernard Escudier, Elizabeth R Plimack, Brian I Rini, Martin H Voss, Hans J Hammers, Chung-Han Lee, Robert J Motzer, Yoshihiko Tomita, Nizar M Tannir, Meredith M Regan, Charlene M Mantia, Lisa Rosenblatt, Opeyemi A Jegede
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background Immunotherapy can be associated with prolonged disease control even after cessation of treatment without the need for further cancer-directed therapy. Treatment-related adverse events (TRAEs) can also persist after discontinuation of thera
Externí odkaz:
https://doaj.org/article/e929a9c890ec467cac7b04eb3f99fada
Autor:
Chung-Wei Lee, Thomas Powles, Sabina Signoretti, David F McDermott, Sumanta K Pal, Toni K Choueiri, Brian I Rini, Saby George, Robert J Motzer, Frede Donskov, Scott S Tykodi, Nizar M Tannir, Saurabh Gupta, Ruiyun Jiang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 12 (2022)
Background Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have a poor prognosis and limited therapeutic options. First-line nivolumab plus ipilimumab (NIVO+IPI) provided efficacy benefits over sunitinib (SUN) in patients
Externí odkaz:
https://doaj.org/article/635447aa98714bc2a7c7b60e0478a8aa
Autor:
Jin Yao, Thomas Powles, David F McDermott, Toni K Choueiri, Petra Ross-MacDonald, Simon Papillon-Cavanagh, Robert J Motzer, M Brent McHenry, Megan Wind-Rotolo, Ron Ammar, Yann-Alexandre Vano, Saurabh Gupta, Celine Han, Shruti S Saggi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background The phase 3 CheckMate 214 trial demonstrated higher response rates and improved overall survival with nivolumab plus ipilimumab versus sunitinib in first-line therapy for advanced clear-cell renal cell carcinoma (RCC). An unmet need exists
Externí odkaz:
https://doaj.org/article/1e556bbcc49144c39a159ece4d4fdec1
Autor:
Howard Gurney, Thomas Powles, Laurence Albiges, Camillo Porta, Toni K Choueiri, Marc-Oliver Grimm, Elizabeth R Plimack, Brian I Rini, Saby George, Robert J Motzer, Frede Donskov, Philippe Barthélémy, Christian K Kollmannsberger, Yoshihiko Tomita, M Brent McHenry, Shruti Shally Saggi, Nizar M Tannir, Mauricio Burotto, Daniel Castellano
Publikováno v:
ESMO Open, Vol 5, Iss 6 (2020)
Purpose To report updated analyses of the phase III CheckMate 214 trial with extended minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab (NIVO+IPI) versus (vs) sunitinib (SUN) in patients with advanced renal cell
Externí odkaz:
https://doaj.org/article/f54750c49b2c4a85a39b1e7b5272d449
Autor:
Howard Gurney, Thomas Powles, Asim Amin, Bohuslav Melichar, Camillo Porta, David F McDermott, Toni K Choueiri, Marc-Oliver Grimm, Bernard Escudier, Elizabeth R Plimack, Brian I Rini, Hans J Hammers, Saby George, Robert J Motzer, Alain Ravaud, Osvaldo Arén Frontera, Frede Donskov, Philippe Barthélémy, Victoria Neiman, Pamela Salman, Christian K Kollmannsberger, Scott S Tykodi, Raya Leibowitz-Amit, Poul F Geertsen, Yoshihiko Tomita, M Brent McHenry, Shruti Shally Saggi, Nizar M Tannir
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background The extent to which response and survival benefits with immunotherapy-based regimens persist informs optimal first-line treatment options. We provide long-term follow-up in patients with advanced renal cell carcinoma (aRCC) receiving first
Externí odkaz:
https://doaj.org/article/633526ea5f4546a1a54c5f374b846edf
Autor:
Toni K. Choueiri, Thomas Powles, Laurence Albiges, Mauricio Burotto, Cezary Szczylik, Bogdan Zurawski, Eduardo Yanez Ruiz, Marco Maruzzo, Alberto Suarez Zaizar, Luis E. Fein, Fabio A. Schutz, Daniel Y.C. Heng, Fong Wang, Fabio Mataveli, Yu-Lin Chang, Maximiliano van Kooten Losio, Cristina Suarez, Robert J. Motzer
Publikováno v:
New England Journal of Medicine. 388:1767-1778
Autor:
Kelly N. Fitzgerald, Cihan Duzgol, Andrea Knezevic, Natalie Shapnik, Ritesh Kotecha, David H. Aggen, Maria I. Carlo, Neil J. Shah, Martin H. Voss, Darren R. Feldman, Robert J. Motzer, Chung-Han Lee
Publikováno v:
European Urology. 83:195-199
Immunotherapy (IO)-based combinations used to treat metastatic clear cell renal cell carcinoma (ccRCC) include dual immune checkpoint inhibition with ipilimumab and nivolumab (IO/IO) and several combinations of vascular endothelial growth factor rece
Autor:
Neil J. Shah, Sneha D. Sura, Reshma Shinde, Junxin Shi, Puneet K. Singhal, Nicholas J. Robert, Nicholas J. Vogelzang, Rodolfo F. Perini, Robert J. Motzer
Publikováno v:
European Urology Open Science. 49:110-118
Publikováno v:
Nature Reviews Urology. 20:179-193
Autor:
Yasser Ged, Alejandro Sanchez, Sujata Patil, Andrea Knezevic, Emily Stein, Stacey Petruzella, Kate Weiss, Cihan Duzgol, Joshua Chaim, Oguz Akin, Marina Mourtzakis, Michael T. Paris, Jessica Scott, Fengshen Kuo, Ritesh Kotecha, A. Ari Hakimi, Chung-Han Lee, Robert J. Motzer, Martin H. Voss, Helena Furberg
Publikováno v:
Clinical Cancer Research. 28:5180-5189
Purpose: High body mass index (BMI) may lead to improved immune-checkpoint blockade (ICB) outcomes in metastatic clear cell renal cell carcinoma (mccRCC). However, BMI is a crude body size measure. We investigated BMI and radiographically assessed bo